28bio's CNS-3D Brain Organoids Demonstrate Superior Seizure Prediction Accuracy Over Animal Models
核心洞察
28bio (搜索)'s Endurance Study achieved 83% sensitivity and 89% specificity in predicting clinical seizure (搜索) liability using CNS (搜索)-3D Brain Organoids, demonstrating 13x higher predictive performance than animal models.
The retrospective study evaluated data from 120,551 patients and focused on seizure (搜索) liability, one of the most challenging CNS (搜索) adverse effects to predict in neurological drug development.
CNS toxicity (搜索) accounts for approximately 25% of failures across drug discovery and development, yet is rarely detected during traditional GLP toxicology studies.
28bio (搜索) announced breakthrough results from its Endurance Study, demonstrating that CNS (搜索)-3D Brain Organoids can predict clinical seizure (搜索) liability in small molecule drugs with 83% sensitivity and 89% specificity. The technology shows 13x higher predictive performance compared to traditional animal models, potentially transforming neurological drug development safety assessment.
Study Design and Methodology
The Endurance Study represents a retrospective, non-interventional evaluation of CNS (搜索)-3D Brain Organoids' predictive performance using documented human clinical outcomes from 120,551 patients and known positive controls. The study specifically targeted seizure (搜索) liability, identified as one of the most challenging and regulatory-critical CNS adverse effects to predict in neurological drug development.
The research evaluated both seizure (搜索)-inducing drugs and clinically safe drugs to establish the technology's discriminatory capabilities. Results not only outperformed animal models but also exceeded previously published data on 2D and 3D cell-based assays while aligning with regulatory agency guideline recommendations.
Addressing Critical Industry Challenges
CNS toxicity (搜索) represents a significant bottleneck in pharmaceutical development, accounting for approximately 25% of failures across drug discovery and development processes. Despite this substantial impact, current GLP toxicology studies rarely detect these effects, highlighting fundamental limitations in animal models for predicting human neurological responses.
"These results show that CNS (搜索)-3D Brain Organoids can predict human CNS outcomes far more accurately than traditional animal models," said Chris Butt, PhD, VP of Technology at 28bio (搜索). "By enabling more reliable drugs to advance into first-in-human trials, this technology can reduce clinical failure across neurological drug development."
Regulatory Alignment and Future Implications
The timing of these results aligns with growing regulatory emphasis on human-relevant safety assessment models. David Weiner, MD, Co-chairman of the Board at 28bio (搜索), noted the regulatory landscape's evolution: "FDA and NIH have both emphasized the need for more reliable, human-relevant models in safety assessment and regulatory decision frameworks. With growing regulatory support for new approach methodologies, studies like Endurance demonstrate how CNS (搜索)-3D Brain Organoids can provide more predictive evidence to guide CNS safety decisions."
Technology Platform
28bio (搜索)'s NexonTM platform integrates tissue engineering, neural interfacing, and artificial intelligence to create human brain organoids exhibiting memory, learning, and cognitive functions. The company positions itself as engineering human brains at-scale to address the current neurological health crisis by improving therapeutic prediction accuracy.
The Endurance Study results will be presented at the Society for Toxicology 65th Annual Meeting in San Diego, California, from March 22-25, 2026, providing the scientific community with detailed methodology and implications for future neurological drug development strategies.